Quan Joanne 4

What Happened

• Joanne Quan, Chief Medical Officer of Mirum Pharmaceuticals (MIRM), received three equity awards on January 28, 2026 totaling 49,900 restricted stock units/performance RSUs: 18,140 RSUs, 11,760 RSUs, and 20,000 PSUs. All were reported as awards (transaction code A) with a $0 purchase price (derivative awards), so no cash was exchanged at grant.

Key Details

• Transaction date: January 28, 2026 (Form 4 filed January 30, 2026 — timely).
• Reported price: $0.00 per share (awards/derivatives); Form 4 shows $0 total value for the grant entries.
• Shares owned after the transaction: not specified in the filing.
• Footnote highlights:
  • F2: Each restricted stock unit represents a contingent right to receive one share of common stock.
  • F1 (applies to one award): 25% vests one year after the January 28, 2026 vesting commencement date; remaining shares vest in 36 equal monthly installments thereafter.
  • F3 (applies to one award): 1/3 vests on each anniversary of January 28, 2026 (fully vested after 3 years).
  • F4 (applies to PSUs): These were PSUs granted Jan 23, 2024; performance criteria were met Jan 28, 2026. Vesting: 2/3 of the PSUs vest March 15, 2026, and 1/3 vest March 15, 2027.
• Transaction type: Awards/grants (derivative RSUs/PSUs), not open-market purchases or sales.

Context

• These are compensation-related equity awards and do not involve a cash purchase or sale of stock at grant; they will convert to shares only as they vest (and for PSUs, upon satisfaction of performance conditions).
• Such grants are routine for executive compensation and are not direct signals of buying or selling by the insider.